- Home
- PLRX vs DXR Comparison
PLRX vs DXR Comparison
Compare PLRX & DXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PLRX | DXR |
|---|---|---|
| Founded | 2015 | 1970 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.1M | 59.0M |
| IPO Year | 2020 | 1995 |
Fundamental Metrics
Financial Performance| Metric | PLRX | DXR |
|---|---|---|
| Price | $0.88 | $10.17 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 6 | 2 |
| Target Price | $2.67 | ★ $20.00 |
| AVG Volume (30 Days) | ★ 371.2K | 23.1K |
| Earning Date | 11-05-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 29.97 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $1,446,345.00 |
| Revenue This Year | N/A | $44,489.33 |
| Revenue Next Year | N/A | $74.79 |
| P/E Ratio | ★ N/A | $33.83 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.96 | $8.56 |
| 52 Week High | $1.95 | $14.76 |
Technical Indicators
Market Signals| Indicator | PLRX | DXR |
|---|---|---|
| Relative Strength Index (RSI) | 24.98 | 39.05 |
| Support Level | N/A | $9.26 |
| Resistance Level | $1.37 | $10.99 |
| Average True Range (ATR) | 0.04 | 0.60 |
| MACD | -0.01 | -0.12 |
| Stochastic Oscillator | 1.59 | 1.88 |
Price Performance
Historical ComparisonAbout PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.
About DXR Daxor Corporation
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA offers unmatched, real-time, precise data via its rapid, hand-held, lab-based system.